All In Biotech

NDA 011719 · Hospira

Methotrexate Preservative Free

Methotrexate Sodium · Injection

Orphan

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1959

Aug 10, 1959

Approved uses

3

Original approval plus efficacy supplements

Registered trials

2,087

570 Phase 3, 211 recruiting

FAERS reports

487,627

358,960 serious, 38,300 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, BENZYL ALCOHOL TOXICITY, and OTHER SERIOUS ADVERSE REACTIONS • Methotrexate Injection can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Methotrexate Injection is contraindicated in pregnancy. Advise females and males of reproductive potential to use effective contraception [see Contraindications (4) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1 , 8.3) ] . • Methotrexate Injection is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis [see Contraindications (4) and Warnings and Precautions (5.2) ]. • Formulations with benzyl alcohol can cause severe central nervous toxicity or metabolic acidosis. Use only preservative-free Methotrexate Injection for treatment of neonates or low birth weight infants and...

What it is approved for

From the label in effect Oct 29, 2026.

Methotrexate Injection is a folate analog metabolic inhibitor indicated for: • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen. ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia. ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma. ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemotherapy regimen. ( 1.5 ) o Treatment of adults with squamous cell carcinoma of the head and neck as a single agent. ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen. ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) 1.1 Acute Lymphoblastic Leukemia Methotrexate Injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy regimen. 1.2 Meningeal Leukemia: Prophylaxis and Treatment Methotrexate Injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. 1.3 Non-Hodgkin Lymphoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with non-Hodgkin lymphoma. 1.4 Osteosarcoma Methotrexate Injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. 1.5 Breast Cancer Methotrexate...

Mechanism: Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate. The mechanism of action in rheumatoid arthritis, pJIA, and in...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 29, 2021 Supplement 131 · Efficacy LabelLetter
  • Apr 7, 1988 Supplement 77 · Efficacy
  • Aug 10, 1959 Original approval · Type 2 - New Active Ingredient
12 products under this application
  • METHOTREXATE PRESERVATIVE FREE · METHOTREXATE SODIUM EQ 20MG BASE/2ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 100MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • METHOTREXATE SODIUM PRESERVATIVE FREE · METHOTREXATE SODIUM EQ 1GM BASE/40ML (EQ 25MG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 2.5MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 50MG BASE/2ML (EQ 25MG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
  • METHOTREXATE SODIUM PRESERVATIVE FREE · METHOTREXATE SODIUM EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • METHOTREXATE LPF · METHOTREXATE SODIUM EQ 25MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • METHOTREXATE PRESERVATIVE FREE · METHOTREXATE SODIUM EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 25MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • METHOTREXATE PRESERVATIVE FREE · METHOTREXATE SODIUM EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 50MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • METHOTREXATE SODIUM · METHOTREXATE SODIUM EQ 20MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Methotrexate" as an intervention, any sponsor and status, largest first.

All 2,087 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective93,085
  • rheumatoid arthritis42,801
  • arthralgia40,718
  • off label use40,573
  • pain39,635
  • fatigue33,027
  • nausea28,920
  • joint swelling24,995
  • drug intolerance24,515
  • condition aggravated23,993
  • headache23,450
  • rash22,590

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045,891
20055,584
20065,149
20078,029
20089,257
20099,418
20109,834
201110,985
201215,617
201317,734
201417,445
201521,279
201625,472
201732,187
201843,779
201940,975
202046,026
202130,926
202234,807
202332,370
202427,844
202523,597
202613,413

Recalls

2 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

  • Jun 27, 2012 · Class II · Terminated

    The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial....

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38).

  • Current · updated Nov 9, 2026

    Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) Multiple Dose Vial PREMIERProRx (NDC 61703-161-05). Other

  • Current · updated Nov 9, 2026

    Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40).

  • Current · updated Nov 9, 2026

    Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25).

  • Current · updated Nov 9, 2026

    Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10).

  • Current · updated Nov 9, 2026

    Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Methotrexate Sodium (Methotrexate Sodium/PF)

2024 spending

$901K

Beneficiaries

18,556

59,947 claims

Per beneficiary

$49

$1.50 per unit

View as table
YearSpending
2020$1,327,068
2021$1,357,555
2022$1,441,309
2023$843,319
2024$901,080

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,151 on PubMed

Sponsor: Pfizer · Also marketed as Methotrexate Sodium, Methotrexate Sodium Preservative Free, Methotrexate Lpf

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.